Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Testing effectiveness (Phase 2)Study completedNCT04661150
What this trial is testing

Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 42
Not applicableStudy completedNCT06585501
What this trial is testing

Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 805
Large-scale testing (Phase 3)Looking for participantsNCT06532006
What this trial is testing

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more
Shanghai Henlius Biotech 550
Large-scale testing (Phase 3)Study completedNCT01662869
What this trial is testing

Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 564
Post-approval studies (Phase 4)Ended earlyNCT01260194
What this trial is testing

Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT05586061
What this trial is testing

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
Qilu Hospital of Shandong University 55
Testing effectiveness (Phase 2)UnknownNCT02901301
What this trial is testing

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

Who this might be right for
Gastric Cancer
Yonsei University 41
Early research (Phase 1)Active Not RecruitingNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 103
Testing effectiveness (Phase 2)UnknownNCT05270889
What this trial is testing

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Who this might be right for
HER2-positive Gastric Cancer
Yonsei University 50
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Not applicableLooking for participantsNCT06767449
What this trial is testing

Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Cancer
Yonsei University 80
Testing effectiveness (Phase 2)Study completedNCT04276493
What this trial is testing

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Cancer
BeiGene 71
Testing effectiveness (Phase 2)Ended earlyNCT01702558
What this trial is testing

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Who this might be right for
Breast CancerGastric Cancer
Hoffmann-La Roche 182
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Study completedNCT01736410
What this trial is testing

Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
HER 2 Positive Advanced Gastric Cancer
National Cancer Centre, Singapore 30
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Testing effectiveness (Phase 2)Study completedNCT01396707
What this trial is testing

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

Who this might be right for
Metastatic or Recurrent Gastric AdenocarcinomaHer-2 Positive Gastric Cancer
Asan Medical Center 55
Next Page